Influence of isoprostane F2α-III on reflow after myocardial infarction

Kim Greaves; S R Dixon; I O Coker; A I Mallet; M Avkiran; M J Shattock; M J Fejka; W W O'Neill; R Senior; S Redwood; M S Marber

doi:10.1016/j.ehj.2004.03.015

Back

Influence of isoprostane F2α-III on reflow after myocardial infarction

Journal article

Peer reviewed

Influence of isoprostane F2α-III on reflow after myocardial infarction

Kim Greaves, S R Dixon, I O Coker, A I Mallet, M Avkiran, M J Shattock, M J Fejka, W W O'Neill, R Senior, S Redwood, …

European Heart Journal, Vol.25(10), pp.847-853

2004

DOI: https://doi.org/10.1016/j.ehj.2004.03.015

Files and links (1)

url

https://doi.org/10.1016/j.ehj.2004.03.015View

Published Version

Abstract

Myocardial infarction

Isoprostanes

reperfusion

Aims: To investigate whether the vasoconstrictor isoprostane F 2?-III (iPF2?-III), released during myocardial reperfusion, contributes to the low/no reflow phenomenon observed following acute myocardial infarction (AMI). Methods and results: Thirteen patients undergoing primary percutaneous coronary intervention (PCI) for AMI had iPF2?-III measured by high-performance liquid and gas chromatography-mass spectrometry. Isoprostane F2?-III concentrations were significantly higher following PCI than in controls (1.5±1.3 vs. 16±0.06 nM, p < 0.001). Mean iPF 2?-III concentration correlated positively with ST-segment resolution at 90 min (R = 0.62, p < 0.05). In the isolated murine heart: (a) coronary vasoconstriction occurred at, or above, iPF2?-III concentrations of 1 ?M. From 1 to 10 ?M, iPF2?-III induced dose-dependent vasoconstriction (p = 0.005) with reduction in coronary flows (CF) of 57±5% and 31±4% (percentage baseline), respectively; (b) SQ29548 1 ?M completely reversed the vasoconstrictive effects of iPF2?-III 10 ?M; (c) SQ29548 1 ?M infused during reperfusion following 30 min ischaemia had no effect on CF or infarct volume. Conclusion: Concentrations of iPF2?-III released into the venous circulation during reperfusion following AMI in humans are significantly lower than those required to diminish coronary flow in the murine heart; increased levels indicate successful reperfusion. Inhibition of iPF 2?-III has no effect on coronary flow or infarct size in the murine heart, suggesting that iPF2?-III alone does not account for the low/no reflow phenomenon observed following AMI. © 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.

Details

Title: Influence of isoprostane F2α-III on reflow after myocardial infarction
Authors: Kim Greaves (Author) - St. Thomas' Hospital, United Kingdom
S R Dixon (Author) - William Beaumont Hospital, United States
I O Coker (Author) - University of Greenwich, United Kingdom
A I Mallet (Author) - University of Greenwich, United Kingdom
M Avkiran (Author) - St. Thomas' Hospital, United Kingdom
M J Shattock (Author) - St. Thomas' Hospital, United Kingdom
M J Fejka (Author) - William Beaumont Hospital, United States
W W O'Neill (Author) - William Beaumont Hospital, United States
R Senior (Author) - Northwich Park Hospital, United Kingdom
S Redwood (Author) - St. Thomas' Hospital, United Kingdom
M S Marber (Author) - St. Thomas' Hospital, United Kingdom
Publication details: European Heart Journal, Vol.25(10), pp.847-853
Publisher: Oxford University Press
Date published: 2004
DOI: 10.1016/j.ehj.2004.03.015
ISSN: 0195-668X
Organisation Unit: Faculty of Science, Health, Education and Engineering; University of the Sunshine Coast, Queensland
Language: English
Record Identifier: 99449551202621
Output Type: Journal article

Metrics

469 Record Views

11 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Cardiac & Cardiovascular Systems

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites